PharmiWeb.com - Global Pharma News & Resources
19-Jul-2019

Scleroderma Therapeutics Market Will Grow 6.4% to a Record $ 3.8 Billion by 2026

The Global Scleroderma Therapeutics Market Size projected to register USD 3.8 billion by 2026, registering at a CAGR growth of 6.4% over the forecast period 2019 to 2026. Acumen Research and Consulting, Recently Published Report titled ldquo;Scleroderma Therapeutics Market Size, Share, Trends and Forecast 2019-2026rdquo;.

Scleroderma is a parachute word for a group of autoimmune illnesses leading to blood vessel, skin, muscle, and other organ modification. Thick and steep skin, lethargy and bad blood flow to limb extremities such as toes and your fingers when exposed to the cold include the symptoms of the Scleroderma. Calcium deposit, Raynaud's syndrome, and esophageal issues may also lead to Scleroderma deposition. Scleroderma is the main driver of the Scleroderma industry with a growing incidence and screening rate. Scleroderma prevalence is indicative of big unmet need in the US of 240 per million and an annual incidence of 19 per million. Scleroderma has an estimated European prevalence of 10-150 per million individuals.

The exposure of silica, aromatic and chlorinated solvents, ketones, fumes and the creation of highly delicate and selective cutaneous biopsy and blood tests is prompting a significant market growth. The exposure is growing at a growing level of risk variables. The elevated recurrence and spread of the disease to systemic death caused by heart, pulmonary and gastrointestinal problems leads to a big market due to low demand elasticity. Systemic Scleroderma incidence is estimated at around 3 per 100,000 individuals per year. As scleroderma mostly starts in the middle ages, the increasing geriatric population is another driver on the market.

Free Download Sample Report Pages for Better Understanding at https://www.acumenresearchandconsulting.com/request-sample/1531

The worldwide leading suppliers of diagnostic and therapeutic scleroderma will invest in fresh growth and development avenues. This involves better studies, strengthened links with health centers and hospitals, and links with pharmaceutical companies. New development strategies are also anticipated to be introduced by small-and medium-scale suppliers in the industry of scleroderma diagnostics and therapeutics.

Due to progress in the field of skin diagnostics the demand for scleroderma and therapeutics in the worldwide industry has increased. Recently, diagnostics of scleroderma have acquired traction in various areas of the healthcare industry. This is because such diagnosis is relevant for patients' general health. In the medical fraternity which has also supported market growth, skin biopsies have become highly prevalent. The popularity of different kinds of imaging methods generated many possibilities on the worldwide therapeutic and scleroderma diagnostic market.

In latest times the incidence of cardiac illnesses improved with the use of electrocardiograms. As electrocardiogram-related exams are subject to diagnostic scleroderma and therapy, the worldwide market has generated important profits through this trend. In the worldwide diagnostics and therapeutical market for sclerodermas, the need for pulmonary function tests has also created loving demand. The increasing popularity of echocardiograms is also anticipated to benefit the worldwide diagnostics and therapeutic market for scleroderma.

In the most matured part of this market, North America. The presence in conjunction with elevated market penetration levels of good governance laws and financing programmes is the key driver for regional market growth. In addition, a large amount of clinical studies is scheduled to be conducted to improve efficacy and new product development in the region. Due the big existence of unsatisfied patient need and consequent increase in utilization, Asia Pacific has emerged as the fastest-growing region. In addition, favourable public policies are projected to drive market development throughout the forecast era in Japan and Australia.

Key Players amp; Strategies

Some of the key players are Active Biotech AB, Allergan, Inc., BioLineRx, Ltd., Bayer AG, Digna Biotech, F. Hoffmann-La Roche Ltd., Angion Biomedica Corp., GlaxoSmithKline plc, Corbus pharmaceuticals, Inc., S.L., Fibrocell Science, Inc. Daval International Ltd., Bristol-Myers Squibb Company and Dynavax Technologies Corporation.

Competitive market dynamics arise through strategic initiatives, which include fusion and acquisitions, partnerships and joint ventures. They focus on implementing development policies such as product portfolio development, mergers and purchases, and advertising activities in order to enhance their presence in unexploited markets worldwide.

View Detail Information with at https://www.acumenresearchandconsulting.com/scleroderma-therapeutics-market

Request for Customization@https://www.acumenresearchandconsulting.com/request-customization/1531

TABLE OF CONTENT

CHAPTER 1. INDUSTRY OVERVIEW

1.1. Definition and Scope
1.1.1. Definition of Scleroderma Therapeutics
1.1.2. Market Segmentation
1.1.3. List of Abbreviations
1.2. Summary
1.2.1. Market Snapshot
1.2.2. Scleroderma Therapeutics Market By Drug Class
1.2.2.1. Global Scleroderma Therapeutics Market Revenue and Growth Rate Comparison By Drug Class (2015-2026)
1.2.2.2. Global Scleroderma Therapeutics Market Revenue Share By Drug Class in 2017
1.2.2.3. Immunosuppressors
1.2.2.4. Endothelin Receptor Antagonists
1.2.2.5. Phosphodiesterase 5 Inhibitors ndash; PHA
1.2.2.6. Calcium Channel Blockers
1.2.2.7. Analgesic
1.2.2.8. Prostacyclin Analogues
1.2.2.9. Others
1.2.3. Scleroderma Therapeutics Market By Indication
1.2.3.1. Global Scleroderma Therapeutics Market Revenue and Growth Rate Comparison By Indication (2015-2026)
1.2.3.2. Global Scleroderma Therapeutics Market Revenue Share By Indication in 2017
1.2.3.3. Systemic
1.2.3.4. Localized
1.2.4. Scleroderma Therapeutics Market by Geography
1.2.4.1. Global Scleroderma Therapeutics Market Revenue and Growth Rate Comparison by Geography (2015-2026)
1.2.4.2. North America Scleroderma Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.3. Europe Scleroderma Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.4. Asia-Pacific Scleroderma Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.5. Latin America Scleroderma Therapeutics Market Revenue and Growth Rate (2015-2026)
1.2.4.6. Middle East and Africa (MEA) Scleroderma Therapeutics Market Revenue and Growth Rate (2015-2026)

CHAPTER 2. MARKET DYNAMICS AND COMPETITION ANALYSIS

2.1. Market Drivers
2.2. Restraints and Challenges
2.3. Growth Opportunities
2.4. Porterrsquo;s Five Forces Analysis
2.4.1. Bargaining Power of Suppliers
2.4.2. Bargaining Power of Buyers
2.4.3. Threat of Substitute
2.4.4. Threat of New Entrants
2.4.5. Degree of Competition
2.5. Value Chain Analysis
2.6. Cost Structure Analysis
2.6.1. Raw Material and Suppliers
2.6.2. Manufacturing Process Analysis
2.7. Regulatory Compliance
2.8. Competitive Landscape, 2017
2.8.1. Player Positioning Analysis
2.8.2. Key Strategies Adopted By Leading Players

CHAPTER 3. MANUFACTURING PLANTS ANALYSIS

3.1. Capacity and Commercial Production Date of Global Scleroderma Therapeutics Major Manufacturers in 2017
3.2. Manufacturing Plants Distribution of Global Scleroderma Therapeutics Major Manufacturers in 2017
3.3. Ramp;D Status and Technology Source of Global Scleroderma Therapeutics Major Manufacturers in 2017
3.4. Raw Materials Sources Analysis of Global Scleroderma Therapeutics Major Manufacturers in 2017

CHAPTER 4. SCLERODERMA THERAPEUTICS MARKET BY DRUG CLASS

4.1. Global Scleroderma Therapeutics Revenue By Drug Class
4.2. Immunosuppressors
4.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.3. Endothelin Receptor Antagonists
4.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.4. Phosphodiesterase 5 Inhibitors - PHA
4.4.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.4.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.5. Calcium Channel Blockers
4.5.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.5.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.6. Analgesic
4.6.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.6.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.7. Prostacyclin Analogues
4.7.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.7.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
4.8. Others
4.8.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
4.8.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 5. SCLERODERMA THERAPEUTICS MARKET BY INDICATION

5.1. Global Scleroderma Therapeutics Revenue By Indication
5.2. Systemic
5.2.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.2.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)
5.3. Localized
5.3.1. Market Revenue and Growth Rate, 2015 - 2026 ($Million)
5.3.2. Market Revenue and Forecast, By Region, 2015 - 2026 ($Million)

CHAPTER 6. NORTH AMERICA SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

6.1. North America Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
6.2. North America Scleroderma Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
6.3. U.S.
6.3.1. U.S. Scleroderma Therapeutics Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
6.4. Canada
6.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
6.5. Mexico
6.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
6.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 7. EUROPE SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

7.1. Europe Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
7.2. Europe Scleroderma Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
7.3. UK
7.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
7.4. Germany
7.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
7.5. France
7.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
7.6. Spain
7.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.6.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
7.7. Rest of Europe
7.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
7.7.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 8. ASIA-PACIFIC SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

8.1. Asia-Pacific Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
8.2. Asia-Pacific Scleroderma Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
8.3. China
8.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.4. Japan
8.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.5. India
8.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.6. Australia
8.6.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.6.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.7. South Korea
8.7.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.7.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
8.8. Rest of Asia-Pacific
8.8.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
8.8.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 9. LATIN AMERICA SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

9.1. Latin America Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
9.2. Latin America Scleroderma Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
9.3. Brazil
9.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.4. Argentina
9.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
9.5. Rest of Latin America
9.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
9.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 10. MIDDLE EAST SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

10.1. Middle East Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
10.2. Middle East Scleroderma Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
10.3. Saudi Arabia
10.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.4. UAE
10.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
10.5. Rest of Middle East
10.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
10.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 11. AFRICA SCLERODERMA THERAPEUTICS MARKET BY COUNTRY

11.1. Africa Scleroderma Therapeutics Market Revenue and Growth Rate, 2015 - 2026 ($Million)
11.2. Africa Scleroderma Therapeutics Market Revenue Share Comparison, 2015 amp; 2026 (%)
11.3. South Africa
11.3.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.3.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.4. Egypt
11.4.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.4.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)
11.5. Rest of Africa
11.5.1. Market Revenue and Forecast By Drug Class, 2015 - 2026 ($Million)
11.5.2. Market Revenue and Forecast By Indication, 2015 - 2026 ($Million)

CHAPTER 12. COMPANY PROFILE

12.1. Active Biotech AB
12.1.1. Company Snapshot
12.1.2. Overview
12.1.3. Financial Overview
12.1.4. Product Portfolio
12.1.5. Key Developments
12.1.6. Strategies
12.2. Allergan, Inc.
12.2.1. Company Snapshot
12.2.2. Overview
12.2.3. Financial Overview
12.2.4. Product Portfolio
12.2.5. Key Developments
12.2.6. Strategies
12.3. BioLineRx, Ltd.
12.3.1. Company Snapshot
12.3.2. Overview
12.3.3. Financial Overview
12.3.4. Product Portfolio
12.3.5. Key Developments
12.3.6. Strategies
12.4. Bayer AG
12.4.1. Company Snapshot
12.4.2. Overview
12.4.3. Financial Overview
12.4.4. Product Portfolio
12.4.5. Key Developments
12.4.6. Strategies
12.5. Digna Biotech
12.5.1. Company Snapshot
12.5.2. Overview
12.5.3. Financial Overview
12.5.4. Product Portfolio
12.5.5. Key Developments
12.5.6. Strategies
12.6. F. Hoffmann-La Roche Ltd.
12.6.1. Company Snapshot
12.6.2. Overview
12.6.3. Financial Overview
12.6.4. Product Portfolio
12.6.5. Key Developments
12.6.6. Strategies
12.7. Angion Biomedica Corp.
12.7.1. Company Snapshot
12.7.2. Overview
12.7.3. Financial Overview
12.7.4. Product Portfolio
12.7.5. Key Developments
12.7.6. Strategies
12.8. GlaxoSmithKline plc
12.8.1. Company Snapshot
12.8.2. Overview
12.8.3. Financial Overview
12.8.4. Product Portfolio
12.8.5. Key Developments
12.8.6. Strategies
12.9. Corbus pharmaceuticals, Inc.
12.9.1. Company Snapshot
12.9.2. Overview
12.9.3. Financial Overview
12.9.4. Product Portfolio
12.9.5. Key Developments
12.9.6. Strategies
12.10. Fibrocell Science, Inc.
12.10.1. Company Snapshot
12.10.2. Overview
12.10.3. Financial Overview
12.10.4. Product Portfolio
12.10.5. Key Developments
12.10.6. Strategies
12.11. Daval International Ltd
12.11.1. Company Snapshot
12.11.2. Overview
12.11.3. Financial Overview
12.11.4. Product Portfolio
12.11.5. Key Developments
12.11.6. Strategies
12.12. Bristol-Myers Squibb Company
12.12.1. Company Snapshot
12.12.2. Overview
12.12.3. Financial Overview
12.12.4. Product Portfolio
12.12.5. Key Developments
12.12.6. Strategies
12.13. Dynavax Technologies Corporation
12.13.1. Company Snapshot
12.13.2. Overview
12.13.3. Financial Overview
12.13.4. Product Portfolio
12.13.5. Key Developments
12.13.6. Strategies
12.14. Others
12.14.1. Company Snapshot
12.14.2. Overview
12.14.3. Financial Overview
12.14.4. Product Portfolio
12.14.5. Key Developments
12.14.6. Strategies

CHAPTER 13. RESEARCH APPROACH

13.1. Research Methodology
13.1.1. Initial Data Search
13.1.2. Secondary Research
13.1.3. Primary Research
13.2. Assumptions and Scope

The report is readily available and can be dispatched immediately after payment confirmation.

Buy this Premium Research Report at https://www.acumenresearchandconsulting.com/buy-now/0/1531

Would like to place an order or any question, please feel free to contact atsales@acumenresearchandconsulting.com| +1 407 915 4157

About Acumen Research and Consulting:

Acumen Research and Consulting (ARC) is a global provider of market intelligence and consulting services to information technology, investment, telecommunication, manufacturing, and consumer technology markets. ARC helps investment communities, IT professionals, and business executives to makefact baseddecisions on technology purchases and develop firm growth strategies to sustain market competition. With the team size of 100+ Analysts and collective industry experience of more than 200 years, Acumen Research and Consulting assures to deliver a combination of industry knowledge along with global and country level expertise.

Editor Details

Last Updated: 19-Jul-2019